Mankind Pharma Ltd - Asset Resilience Ratio

Latest as of September 2025: 8.83%

Mankind Pharma Ltd (MANKIND) has an Asset Resilience Ratio of 8.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MANKIND FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

Rs25.45 Billion

≈ $275.27 Million USD Cash + Short-term Investments

Total Assets

Rs288.13 Billion

≈ $3.12 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Mankind Pharma Ltd's Asset Resilience Ratio has changed over time. See Mankind Pharma Ltd (MANKIND) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Mankind Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MANKIND market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs25.45 Billion	8.83%
Total Liquid Assets	Rs25.45 Billion	8.83%

Asset Resilience Insights

Limited Liquidity: Mankind Pharma Ltd maintains only 8.83% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Mankind Pharma Ltd Industry Peers by Asset Resilience Ratio

Compare Mankind Pharma Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Mankind Pharma Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Mankind Pharma Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	6.09%	Rs16.91 Billion ≈ $182.86 Million	Rs277.60 Billion ≈ $3.00 Billion	-0.15pp
2024-03-31	6.24%	Rs7.46 Billion ≈ $80.72 Million	Rs119.63 Billion ≈ $1.29 Billion	-6.36pp
2023-03-31	12.60%	Rs12.24 Billion ≈ $132.35 Million	Rs97.15 Billion ≈ $1.05 Billion	+1.92pp
2022-03-31	10.68%	Rs9.77 Billion ≈ $105.63 Million	Rs91.48 Billion ≈ $989.29 Million	-18.15pp
2021-03-31	28.83%	Rs18.37 Billion ≈ $198.70 Million	Rs63.73 Billion ≈ $689.18 Million	+11.91pp
2020-03-31	16.92%	Rs8.58 Billion ≈ $92.82 Million	Rs50.73 Billion ≈ $548.66 Million	+16.32pp
2019-03-31	0.60%	Rs246.21 Million ≈ $2.66 Million	Rs41.12 Billion ≈ $444.74 Million	--

pp = percentage points

About Mankind Pharma Ltd

NSE:MANKIND India Drug Manufacturers - Specialty & Generic

Market Cap

$10.52 Billion

Rs972.65 Billion INR

Market Cap Rank

#2186 Global

#87 in India

Share Price

Rs2356.20

Change (1 day)

-1.01%

52-Week Range

Rs1927.40 - Rs2696.50

All Time High

Rs2998.40